The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Monday Deal Review: February 16, 2009

An interesting collection of goings-on in this week’s special President’s Day / Family Day edition of the Monday Deal Review

Follow-on tranches:

Debenture conversion:

Share consolidation:

  • Jovian Capital Corporation (TSX: JOV) announced on February 9th its intention to seek approval to consolidate (20:1) its common shares. Jovian currently has 167,867,555 common shares issued and outstanding.  The shares closed Friday at 0.2750.  The special meeting is March 5th.

Cost-cutting and deal solicitation:

Will RTO for cash:

Not really a deal, but some good news:

  • Orcrist Bio announced that it had filed for a Phase I trial of its lead compound, “a patent-protected formulation of hyaluronan.”  Ocrist is privately held and based in Calgary.

Bookmark and Share

About these ads

3 responses to “Monday Deal Review: February 16, 2009

  1. Pingback: Monday Deal Review: February 23, 2009 « The Cross-Border Biotech Blog

  2. Pingback: Monday Deal Review: March 2, 2009 « The Cross-Border Biotech Blog

  3. Pingback: Monday Deal Review: June 29, 2009 « The Cross-Border Biotech Blog

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 130 other followers